JUNS has undergone a complete business transformation from a resveratrol-focused clinical research company to a pharmaceutical company dependent on an Aquanova license agreement, while simultaneously experiencing severe financial deterioration including negative stockholders' equity and substantial doubt about going concern status.
This represents a fundamental pivot in the company's core business model and technology platform, moving away from their proprietary JOTROL resveratrol formulation to complete dependence on a third-party licensing arrangement. The addition of going concern warnings from both management and auditors, combined with new risks around convertible debt financing difficulties, signals immediate existential threats to the company's survival.
The financial picture shows a company in severe distress, with R&D expenses surging 324% to $2.1M while net losses nearly tripled to $8.6M and stockholders' equity turned deeply negative at -$1.8M. Current liabilities exploded 268% to $7.4M, creating a dire liquidity situation where total liabilities now exceed total assets, and operating cash flow deteriorated further to -$5.4M. This combination of accelerating losses, negative equity, and overwhelming debt burden confirms the going concern warnings and suggests the company faces immediate financial crisis.
R&D investment increased 323.5% — signals commitment to future product development, though near-term margin impact.
Current liabilities surged 268.1% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 264.3% — significant increase in debt or obligations, assess impact on financial flexibility.
Net income declined 254.4% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Operating cash flow fell 38.4% — earnings quality concerns; investigate working capital changes and non-cash items.
Total assets contracted 10.3% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →